| Literature DB >> 34500688 |
Andrea Gómez-Maqueo1,2,3, Dora Steurer1, Jorge Welti-Chanes2, M Pilar Cano1.
Abstract
High hydrostatic pressure (HHP) is a commercial processing technology which can enhance the health potential of foods by improving the bioaccessibility of their bioactive compounds. Our aim was to study the bioaccessibility and digestive stability of phenolic compounds and betalains in prickly pear fruits (Opuntia ficus-indica L. Mill. var. Pelota and Sanguinos) treated with HHP (100, 350, and 600 MPa; come-up time and 5 min). The effects of HHP on pulps (edible fraction) and peels (sources of potential healthy ingredients) were assessed. In pulps, betanin bioaccessibility increased (+47% to +64%) when treated at 350 MPa/5 min. In HHP-treated pulps, increases in the bioaccessibility of piscidic acid (+67% to +176%) and 4-hydroxybenzoic acid glycoside (+126% to 136%) were also observed. Isorhamnetin glycosides in peels treated at 600 MPa/CUT had higher bioaccessibility (+17% to +126%) than their controls. The effects of HHP on the bioaccessibility of health-promoting compounds are not exclusively governed by extractability increases of antioxidants in the food matrix (direct effects). In this work we found evidence that indirect effects (effects on the food matrix) could also play a role in the increased bioaccessibility of antioxidants in fruits treated with HHP.Entities:
Keywords: Opuntia ficus-indica; betalains; bioaccessibility; digestive stability; high hydrostatic pressure; phenolic compounds
Mesh:
Substances:
Year: 2021 PMID: 34500688 PMCID: PMC8434551 DOI: 10.3390/molecules26175252
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Betalain and phenolic content (mg/100 g fresh weight) in rehydrated Sanguinos and Pelota prickly pear (Opuntia ficus-indica L. Mill.) peels and pulps.
| Sanguinos | Pelota | |||
|---|---|---|---|---|
| Compound | Pulp | Peel | Pulp | Peel |
| Indicaxanthin | 0.90 ± 0.05 | 0.60 ± 0.01 | 3.92 ± 0.24 * | 1.01 ± 0.01 * |
| Betanin | 2.05 ± 0.02 | 5.78 ± 0.23 | 27.91 ± 0.45 * | 16.29 ± 0.10 * |
| Piscidic acid | 58.43 ± 3.53 | 439.45 ± 0.90 | 195.63 ± 1.48 * | 779.17 ± 4.74 * |
| 4-hydroxybenzoic acid glycoside | 1.25 ± 0.13 | 19.12 ± 0.21 | 4.47 ± 1.17 | 23.62 ± 0.14 * |
| Isorhamnetin glucosyl-rhamnosyl-rhamnoside (IG1) | n.d. | 0.55 ± 0.03 | n.d. | 1.44 ± 0.01 * |
| Isorhamnetin glucosyl-rhamnosyl-pentoside (IG2) | n.d. | 1.51 ± 0.13 | n.d. | 0.35 ± 0.00 * |
| Isorhamnetin hexosyl-hexosyl-pentoside (IG3) | n.d. | 0.32 ± 0.03 | n.d. | 0.15 ± 0.00 * |
| Isorhamnetin glucosyl-pentoside (IG4) | n.d. | 0.81 ± 0.06 | n.d. | 0.23 ± 0.00 * |
| Isorhamnetin glucosyl-rhamnoside (IG5) | n.d. | 3.09 ± 0.18 | n.d. | 2.26 ± 0.01 * |
Results are expressed as mean ± standard deviation (n = 3). Lowercase superscript letters indicate statistically significant differences (p ≤ 0.05) between peels and pulps. * Indicate statistically significant differences (p ≤ 0.05) between varieties. n.d. not detected.
Initial content (mg/100 g weight) and in vitro bioaccessibility of betalains and phenolic compounds in HHP-treated (100 MPa, 350 MPa, 600 MPa; CUT and 5 min) Sanguinos and Pelota prickly pear pulps and in untreated (control) pulps.
| Prickly Pear ( | |||||
|---|---|---|---|---|---|
| Sanguinos | Pelota | ||||
| Treatment | Pulp (mg/100 g Weight) 1 | Bioaccessibility (%) | Pulp (mg/100 g Weight) 1 | Bioaccessibility (%) | |
| Indicaxanthin | Control | 0.90 ± 0.05a | 53.05 ± 3.01c | 3.92 ± 0.24c | 54.87 ± 2.49bc |
| 100 MPa/CUT | 0.73 ± 0.05a | 40.93 ± 3.27b | 3.62 ± 0.17bc | 52.81 ± 5.17bc | |
| 350 MPa/CUT | 0.90 ± 0.07a | 44.81 ± 2.24bc* | 5.38 ± 0.05d | 64.83 ± 5.19c | |
| 600 MPa/CUT | 0.72 ± 0.06a | 25.30 ± 2.02a* | 2.85 ± 0.16ab | 36.78 ± 2.94a | |
| 100 MPa/5 min | 0.86 ± 0.07a | 28.84 ± 2.31a* | 3.51 ± 0.14bc | 46.87 ± 3.28ab | |
| 350 MPa/5 min | 0.84 ± 0.06a | 46.98 ± 3.29bc | 3.21 ± 0.08abc | 55.38 ± 2.22bc | |
| 600 MPa/5 min | 0.71 ± 0.01a | 22.33 ± 1.79a* | 2.65 ± 0.50a | 43.12 ± 3.45ab | |
| Betanin | Control | 2.05 ± 0.02a | 42.49 ± 2.69c | 27.91 ± 0.45ab | 44.92 ± 1.52ab |
| 100 MPa/CUT | 1.80 ± 0.07a | 35.10 ± 2.81bc | 28.44 ± 0.73ab | 48.50 ± 4.74b | |
| 350 MPa/CUT | 2.32 ± 0.23a | 43.01 ± 3.44c | 35.02 ± 0.00b | 50.65 ± 4.05b | |
| 600 MPa/CUT | 2.14 ± 0.22a | 28.67 ± 1.43ab* | 27.93 ± 1.64ab | 39.23 ± 3.14ab | |
| 100 MPa/5 min | 1.98 ± 0.14a | 25.98 ± 1.82ab* | 26.44 ± 1.79a | 35.21 ± 2.46a | |
| 350 MPa/5 min | 2.19 ± 0.23a | 69.57 ± 5.57d* | 25.79 ± 0.27a | 65.88 ± 2.64c | |
| 600 MPa/5 min | 2.02 ± 0.23a | 20.51 ± 1.64a* | 24.79 ± 4.91a | 46.95 ± 3.76ab | |
| Piscidic acid | Control | 58.43 ± 3.53a | 53.61 ± 4.29ab* | 195.63 ± 1.48a | 38.49 ± 3.08a |
| 100 MPa/CUT | 63.32 ± 7.10a | 56.66 ± 4.53abc* | 255.44 ± 15.40bc | 82.25 ± 6.58cd | |
| 350 MPa/CUT | 71.46 ± 1.26ab | 58.61 ± 3.44abc | 223.96 ± 3.82ab | 62.71 ± 5.02bc | |
| 600 MPa/CUT | 92.66 ± 9.61b | 65.68 ± 5.25bc | 311.03 ± 17.41d | 71.56 ± 3.58bcd | |
| 100 MPa/5 min | 62.78 ± 1.89a | 73.70 ± 1.05cd* | 235.34 ± 15.86abc | 54.39 ± 3.81ab | |
| 350 MPa/5 min | 73.82 ± 8.70ab | 89.36 ± 7.15d | 273.68 ± 2.09bc | 106.20 ± 8.50e | |
| 600 MPa/5 min | 81.97 ± 9.50ab | 42.40 ± 3.39a* | 287.35 ± 29.07cd | 88.43 ± 7.07de | |
| 4-hydrozybenzoic acid glycoside | Control | 1.25 ± 0.13a | 20.00 ± 1.60a | 4.47 ± 1.17a | 17.00 ± 1.36a |
| 100 MPa/CUT | 1.54 ± 0.40ab | 28.53 ± 2.79b | 5.76 ± 0.45ab | 25.89 ± 2.07b | |
| 350 MPa/CUT | 1.87 ± 0.17abc | 27.43 ± 2.19ab | 4.09 ± 0.03a | 21.09 ± 1.24ab | |
| 600 MPa/CUT | 2.48 ± 0.28c | 20.28 ± 1.62a | 9.87 ± 0.47c | 16.76 ± 1.34a | |
| 100 MPa/5 min | 1.60 ± 0.07ab | 22.10 ± 1.55ab | 7.69 ± 0.84bc | 22.81 ± 1.82ab | |
| 350 MPa/5 min | 2.18 ± 0.07bc | 47.13 ± 1.89c | 6.70 ± 0.14ab | 38.44 ± 3.08c | |
| 600 MPa/5 min | 2.19 ± 0.27bc | 19.18 ± 1.53a* | 8.38 ± 1.69bc | 37.48 ± 3.00c | |
Results are expressed as mean ± standard deviation (n = 3). Superscript letters indicate statistically significant differences (p ≤ 0.05) between treatments. * Indicates statistically significant differences (p ≤ 0.05) in bioaccessibility between Pelota and Sanguinos varieties. 1 Data previously reported [11].
Initial content (mg/100 g weight) and in vitro bioaccessibility of betalains and phenolic compounds in HHP-treated (100 MPa, 350 MPa, 600 MPa; CUT and 5 min) Sanguinos and Pelota prickly pear peels and in untreated (control) peels.
| Prickly Pear ( | |||||
|---|---|---|---|---|---|
| Sanguinos | Pelota | ||||
| Compound | Treatment | Peel (mg/100 g Fresh Weight) 1 | Bioaccessibility (%) | Peel (mg/100 g Fresh Weight) 1 | Bioaccessibility (%) |
| Indicaxanthin | Control | 0.60 ± 0.01b | 61.98 ± 3.70d | 1.01 ± 0.01c | 55.39 ± 2.90d |
| 100 MPa/CUT | 0.53 ± 0.01ab | 23.64 ± 1.89ab* | 0.85 ± 0.06bc | 49.35 ± 3.95cd | |
| 350 MPa/CUT | 0.58 ± 0.03ab | 41.54 ± 3.32c | 0.80 ± 0.01b | 48.92 ± 3.91cd | |
| 600 MPa/CUT | 0.53 ± 0.03ab | 33.50 ± 4.55bc | 0.57 ± 0.06a | 38.58 ± 3.09abc | |
| 100 MPa/5 min | 0.55 ± 0.03ab | 19.93 ± 1.59a* | 0.74 ± 0.01ab | 45.76 ± 3.66bcd | |
| 350 MPa/5 min | 0.62 ± 0.04b | 37.82 ± 3.03c | 0.92 ± 0.12bc | 35.23 ± 2.82ab | |
| 600 MPa/5 min | 0.49 ± 0.00a | 33.50 ± 4.21bc | 0.55 ± 0.02a | 30.24 ± 2.42a | |
| Betanin | Control | 5.78 ± 0.23d | 28.88 ± 2.31d* | 16.29 ± 0.10d | 46.11 ± 3.69b |
| 100 MPa/CUT | 3.77 ± 0.23b | 3.58 ± 0.29a* | 15.39 ± 0.89cd | 29.54 ± 2.36a | |
| 350 MPa/CUT | 4.48 ± 0.38bc | 11.98 ± 0.96b* | 12.30 ± 0.00b | 32.13 ± 2.57a | |
| 600 MPa/CUT | 4.52 ± 0.28bc | 22.84 ± 1.83c* | 13.92 ± 1.06bc | 31.36 ± 2.51a | |
| 100 MPa/5 min | 3.76 ± 0.44b | 1.17 ± 0.09a* | 12.66 ± 0.24b | 31.60 ± 2.53a | |
| 350 MPa/5 min | 5.26 ± 0.53cd | 20.16 ± 1.61c* | 15.39 ± 0.45cd | 30.36 ± 2.43a | |
| 600 MPa/5 min | 2.02 ± 0.23a | 36.80 ± 2.94e | 10.30 ± 058a | 32.36 ± 2.59a | |
| Piscidic acid | Control | 439.45 ± 0.90c | 52.36 ± 4.19a | 779.17 ± 4.74ab | 52.71 ± 4.22ab |
| 100 MPa/CUT | 358.85 ± 5.05ab | 55.90 ± 4.47a | 821.22 ± 60.40ab | 53.79 ± 4.30ab | |
| 350 MPa/CUT | 398.36 ± 14.95bc | 45.09 ± 3.61a | 721.33 ± 0.18ab | 59.40 ± 4.75ab | |
| 600 MPa/CUT | 346.51 ± 18.65ab | 54.78 ± 4.38a | 713.46 ± 59.11ab | 46.83 ± 3.75a | |
| 100 MPa/5 min | 393.96 ± 13.37bc | 48.68 ± 3.89a | 689.55 ± 0.20a | 55.06 ± 4.40ab | |
| 350 MPa/5 min | 385.99 ± 35.08bc | 45.88 ± 3.67a | 847.09 ± 31.12b | 62.40 ± 4.99ab | |
| 600 MPa/5 min | 311.32 ± 0.51a | 47.26 ± 3.78a* | 750.60 ± 33.40ab | 69.96 ± 5.60b | |
| 4-hydroxybenzoic acid glycoside | Control | 19.12 ± 0.21d | 60.67 ± 4.85ab | 23.62 ± 0.14a | 65.55 ± 5.24a |
| 100 MPa/CUT | 16.37 ± 0.28bc | 65.38 ± 5.23abc | 24.12 ± 2.67a | 63.29 ± 5.06a | |
| 350 MPa/CUT | 17.47 ± 1.61cd | 50.81 ± 4.06a | 21.04 ± 0.09a | 67.86 ± 5.43ab | |
| 600 MPa/CUT | 14.38 ± 0.73b | 80.54 ± 6.44c | 25.67 ± 2.20a | 89.34 ± 7.15bc | |
| 100 MPa/5 min | 19.54 ± 0.18d | 74.89 ± 5.99bc | 36.83 ± 1.04b | 102.28 ± 8.18c | |
| 350 MPa/5 min | 19.08 ± 0.18d | 61.62 ± 4.93ab | 23.02 ± 0.90a | 71.36 ± 5.71ab | |
| 600 MPa/5 min | 12.07 ± 0.02a | 60.19 ± 4.82ab | 25.92 ± 0.59a | 80.91 ± 6.47abc | |
| IG1 2 | Control | 0.54 ± 0.02ab | 56.20 ± 4.50ab | 1.44 ± 0.01b | 53.30 ± 4.26bc |
| 100 MPa/CUT | 0.61 ± 0.03bc | 82.13 ± 6.57c* | 0.86 ± 0.08a | 25.64 ± 2.05a | |
| 350 MPa/CUT | 0.63 ± 0.01bc | 72.46 ± 5.80bc | 2.39 ± 0.04c | 76.75 ± 6.30d | |
| 600 MPa/CUT | 0.66 ± 0.06c | 84.06 ± 6.72c* | 2.79 ± 0.17d | 120.15 ± 9.61e | |
| 100 MPa/5 min | 0.67 ± 0.04c | 67.63 ± 5.41abc* | 1.44 ± 0.05b | 40.29 ± 3.22ab | |
| 350 MPa/5 min | 0.67 ± 0.01c | 77.29 ± 6.18c* | 3.21 ± 0.04e | 108.06 ± 8.64e | |
| 600 MPa/5 min | 0.50 ± 0.00a | 48.31 ± 3.86a | 3.18 ± 0.01e | 65.93 ± 5.27cd | |
| IG2 3 | Control | 1.50 ± 0.13a | 41.80 ± 3.34a* | 0.35 ± 0.00b | 72.56 ± 5.80bc |
| 100 MPa/CUT | 1.37 ± 0.24a | 54.32 ± 4.35bc* | 0.20 ± 0.01a | 24.27 ± 1.94a | |
| 350 MPa/CUT | 1.44 ± 0.11a | 40.56 ± 3.24a* | 0.56 ± 0.03c | 85.27 ± 6.82cd | |
| 600 MPa/CUT | 1.50 ± 0.06a | 59.10 ± 4.73c* | 0.64 ± 0.05c | 99.02 ± 7.92de | |
| 100 MPa/5 min | 1.71 ± 0.12a | 38.03 ± 3.04a | 0.34 ± 0.01b | 34.93 ± 2.79a | |
| 350 MPa/5 min | 1.70 ± 0.01a | 43.88 ± 3.51ab* | 0.73 ± 0.00d | 110.44 ± 8.84e | |
| 600 MPa/5 min | 1.30 ± 0.00a | 36.55 ± 2.92a* | 0.74 ± 0.03d | 63.44 ± 5.08b | |
| IG3 4 | Control | 0.32 ± 0.03ab | 48.05 ± 3.84c | 0.15 ± 0.00c | 56.89 ± 4.55bc |
| 100 MPa/CUT | 0.29 ± 0.03ab | 42.56 ± 3.40bc* | 0.11 ± 0.00b | 23.52 ± 1.88a | |
| 350 MPa/CUT | 0.31 ± 0.02ab | 33.20 ± 2.66b* | 0.20 ± 0.01d | 59.04 ± 4.72bc | |
| 600 MPa/CUT | 0.32 ± 0.01ab | 62.51 ± 5.00d* | 0.23 ± 0.01e | 93.69 ± 7.50d | |
| 100 MPa/5 min | 0.36 ± 0.00b | 31.78 ± 2.54b* | 0.15 ± 0.00c | 15.68 ± 1.25a | |
| 350 MPa/5 min | 0.34 ± 0.01ab | 37.74 ± 3.02bc* | 0.08 ± 0.00a | 61.50 ± 4.92c | |
| 600 MPa/5 min | 0.28 ± 0.00a | 16.63 ± 1.33a* | 0.08 ± 0.02a | 43.97 ± 3.52b | |
| IG4 5 | Control | 0.82 ± 0.06ab | 59.49 ± 4.76cd | 0.23 ± 0.00b | 58.74 ± 4.70bc |
| 100 MPa/CUT | 0.52 ± 0.20a | 52.26 ± 4.18c* | 0.12 ± 0.00a | 22.68 ± 1.81a | |
| 350 MPa/CUT | 0.55 ± 0.09ab | 61.83 ± 4.95cd | 0.42 ± 0.00c | 85.85 ± 6.87de | |
| 600 MPa/CUT | 0.71 ± 0.03ab | 68.59 ± 5.49d | 0.44 ± 0.04cd | 75.20 ± 6.02cd | |
| 100 MPa/5 min | 0.87 ± 0.05b | 21.56 ± 1.72a | 0.23 ± 0.01b | 24.88 ± 1.99a | |
| 350 MPa/5 min | 0.86 ± 0.01b | 39.20 ± 3.14b* | 0.49 ± 0.00d | 99.19 ± 7.93e | |
| 600 MPa/5 min | 0.56 ± 0.01ab | 35.00 ± 2.80b* | 0.51 ± 0.04d | 53.90 ± 4.31b | |
| IG5 6 | Control | 3.10 ± 0.18b | 29.77 ± 2.38b* | 2.27 ± 0.01b | 55.45 ± 4.44b |
| 100 MPa/CUT | 2.44 ± 0.18ab | 43.05 ± 3.44c* | 1.22 ± 0.06a | 24.45 ± 1.96a | |
| 350 MPa/CUT | 2.12 ± 0.15a | 26.81 ± 2.14b* | 4.31 ± 0.45c | 99.96 ± 8.00c | |
| 600 MPa/CUT | 2.82 ± 0.10ab | 42.10 ± 3.37c* | 5.10 ± 0.49c | 97.67 ± 7.81c | |
| 100 MPa/5 min | 3.11 ± 0.35b | 11.94 ± 0.96a* | 2.20 ± 0.03b | 39.91 ± 3.19ab | |
| 350 MPa/5 min | 3.14 ± 0.39b | 28.05 ± 2.24b* | 5.21 ± 0.05c | 137.52 ± 11.00d | |
| 600 MPa/5 min | 2.16 ± 0.00a | 25.38 ± 2.03b* | 5.12 ± 0.45c | 59.11 ± 4.73b | |
Results are expressed as mean ± standard deviation (n = 3). Superscript letters indicate statistically significant differences (p ≤ 0.05) between treatments. * Indicates statistically significant differences (p ≤ 0.05) in bioaccessibility between Pelota and Sanguinos varieties. 1 Data previously reported [11], 2 isorhamnetin glucosyl-rhamnosyl-rhamnoside (IG1), 3 isorhamnetin glucosyl-rhamnosyl-pentoside (IG2), 4 isorhamnetin hexosyl-hexosyl-pentoside (IG3), 5 isorhamnetin glucosyl-pentoside (IG4), 6 isorhamnetin glucosyl-rhamnoside (IG5).
In vitro digestive stability (mg/100 g fresh weight) of betalains and phenolic compounds in HHP-treated (350 MPa/5 min) Sanguinos and Pelota prickly pear pulps.
| Treatment | Pulp | Oral Phase | Gastric Phase | Intestinal Phase | ||||
|---|---|---|---|---|---|---|---|---|
| Content 1 | Content 1 | Recovery (%) | Content 1 | Recovery (%) | Content 1 | Recovery (%) | ||
| Indicaxanthin | Sanguinos Control | 0.90 ± 0.05c | 0.82 ± 0.02bc | 91 ± 3b | 0.75 ± 0.02b | 83 ± 3b | 0.48 ± 0.03a | 53 ± 3a |
| Sanguinos 350 MPa/5 min | 0.84 ± 0.06a | 1.10 ± 0.06a | 131 ± 16b | 1.01 ± 0.34a | 120 ± 11b | 0.42 ± 0.03a | 51 ± 4a | |
| Pelota Control | 3.92 ± 0.24b | 4.09 ± 0.32b | 104 ± 2c | 3.57 ± 0.09b | 91 ± 3b | 2.15 ± 0.17a | 54 ± 2a | |
| Pelota 350 MPa/5 min | 3.21 ± 0.08b | 3.60 ± 0.43b | 112 ± 11b | 3.46 ± 0.17b* | 108 ± 3b* | 2.17 ± 0.17a | 68 ± 5a | |
| Betanin | Sanguinos Control | 2.05 ± 0.02d | 1.31 ± 0.07c | 64 ± 3c | 1.04 ± 0.05b | 51 ± 2b | 0.87 ± 0.06a | 42 ± 3a |
| Sanguinos 350 MPa/5 min | 2.19 ± 0.23ab | 3.67 ± 0.08b* | 168 ± 14b* | 3.24 ± 0.79b | 148 ± 21b* | 1.42 ± 0.11a* | 65 ± 5a* | |
| Pelota Control | 27.91 ± 0.45c | 29.68 ± 1.31c | 106 ± 3c | 25.76 ± 0.82b | 92 ± 1b | 12.54 ± 0.50a | 45 ± 3a | |
| Pelota 350 MPa/5 min | 25.79 ± 0.27b* | 23.54 ± 2.01b | 91 ± 7a | 22.78 ± 1.47b | 88 ± 5a | 18.39 ± 1.47a* | 71 ± 6a* | |
| Piscidic acid | Sanguinos Control | 58.43 ± 3.53b | 50.40 ± 2.52b | 86 ± 1b | 54.87 ± 2.74b | 94 ± 1c | 31.32 ± 2.51a | 54 ± 4a |
| Sanguinos 350 MPa/5 min | 73.82 ± 8.70ab | 78.30 ± 12.98ab | 106 ± 5b* | 107.36 ± 17.19b* | 145 ± 6c* | 52.21 ± 4.18a* | 71 ± 6a* | |
| Pelota Control | 195.63 ± 1.48d | 163.24 ± 1.52c | 83 ± 0c | 106.36 ± 3.62b | 54 ± 1b | 75.30 ± 6.02a | 38 ± 3a | |
| Pelota 350 MPa/5 min | 273.68 ± 2.09b* | 267.30 ± 25.06b* | 98 ± 8a | 238.01 ± 19.18ab* | 87 ± 6a | 207.76 ± 16.62a* | 76 ± 6a* | |
| 4-hydroxy | Sanguinos Control | 1.25 ± 0.13b | 1.05 ± 0.05b | 84 ± 5b | 2.05 ± 0.10c | 164 ± 9c | 0.25 ± 0.02a | 20 ± 2a |
| Sanguinos 350 MPa/5 min | 2.18 ± 0.07b* | 3.06 ± 0.61b* | 140 ± 23b | 3.49 ± 0.50b | 160 ± 18b | 0.59 ± 0.05a* | 27 ± 2a* | |
| Pelota Control | 4.47 ± 1.17b | 6.39 ± 0.12b | 143 ± 35b | 6.02 ± 0.24b | 135 ± 31b | 0.76 ± 0.06a | 17 ± 1a | |
| Pelota 350 MPa/5 min | 6.70 ± 0.14b | 7.40 ± 0.57b | 110 ± 6b | 8.49 ± 0.57c* | 127 ± 1b | 1.72 ± 0.14a* | 26 ± 2a | |
1 mg/100 g fresh weight. Results are expressed as mean ± standard deviation (n = 3). Superscript lowercase letters indicate statistically significant differences (p ≤ 0.05) between digestive phases.* Indicate statistically significant differences (p ≤ 0.05) between treatments for the same variety.
In vitro digestive stability (mg/100 g fresh weight) of betalains and phenolic compounds in HHP-treated (600 MPa/CUT) Sanguinos and Pelota prickly pear peels.
| Treatment | Peel | Oral Phase | Gastric Phase | Intestinal Phase | ||||
|---|---|---|---|---|---|---|---|---|
| Content 1 | Content 1 | Recovery (%) | Content 1 | Recovery (%) | Content 1 | Recovery (%) | ||
| Indicaxanthin | Sanguinos Control | 0.60 ± 0.01b | 0.63 ± 0.03b | 105 ± 3b | 0.40 ± 0.01a | 66 ± 1a | 0.37 ± 0.02a | 62 ± 4a |
| Sanguinos 600 MPa/CUT | 0.53 ± 0.03a | 0.55 ± 0.08a | 104 ± 8a | 0.50 ± 0.16a | 94 ± 25a | 0.20 ± 0.03a* | 39 ± 5a* | |
| Pelota Control | 1.01 ± 0.01c | 0.98 ± 0.06c | 97 ± 5c | 0.78 ± 0.07b | 77 ± 6b | 0.56 ± 0.03a | 55 ± 3a | |
| Pelota 600 MPa/CUT | 0.57 ± 0.06b* | 0.65 ± 0.04b* | 113 ± 5b | 0.64 ± 0.07b | 112 ± 0b* | 0.39 ± 0.03a* | 68 ± 5a | |
| Betanin | Sanguinos Control | 5.78 ± 0.23c | 5.40 ± 0.50c | 93 ± 5c | 4.06 ± 0.46b | 70 ± 5b | 1.67 ± 0.13a | 29 ± 2a |
| Sanguinos 600 MPa/CUT | 4.52 ± 0.28b* | 5.18 ± 0.06b | 115 ± 6b | 5.00 ± 0.53b | 111 ± 5b* | 1.32 ± 0.11a* | 29 ± 2a | |
| Pelota Control | 16.29 ± 0.10b | 17.73 ± 1.47b | 109 ± 8b | 15.90 ± 2.13b | 98 ± 12b | 7.51 ± 0.60a | 46 ± 4a | |
| Pelota 600 MPa/CUT | 13.92 ± 1.06b | 13.20 ± 0.59b | 95 ± 3b | 12.50 ± 1.06b | 90 ± 1b | 5.11 ± 0.75a* | 37 ± 3a | |
| Piscidic acid | Sanguinos Control | 439.45 ± 0.90b | 463.24 ± 5.65b | 105 ± 1b | 401.20 ± 33.23b | 91 ± 7b | 230.10 ± 18.41a | 52 ± 4a |
| Sanguinos 600 MPa/CUT | 346.50 ± 18.65b* | 373.12 ± 8.66b* | 108 ± 3b | 454.47 ± 34.38c | 131 ± 3c* | 208.83 ± 16.70a | 60 ± 5a | |
| Pelota Control | 779.17 ± 4.74b | 785.43 ± 40.00b | 101 ± 4b | 772.12 ± 36.45b | 99 ± 4b | 410.70 ± 32.86a | 53 ± 4a | |
| Pelota 600 MPa/CUT | 713.46 ± 59.11b | 720.35 ± 39.82b | 101 ± 3b | 839.20 ± 49.96b | 118 ± 3c* | 364.88 ± 29.19a | 51 ± 4a | |
| 4-hydroxy | Sanguinos Control | 19.12 ± 0.21b | 20.57 ± 1.90b | 108 ± 9b | 17.45 ± 2.31b | 91 ± 11ab | 11.60 ± 0.93a | 61 ± 5a |
| Sanguinos 600 MPa/CUT | 14.38 ± 0.73a* | 16.47 ± 1.46a | 114 ± 4b | 17.61 ± 0.46a | 122 ± 3ab | 15.40 ± 1.23a | 107 ± 9a* | |
| Pelota Control | 23.62 ± 0.14ab | 27.44 ± 3.71b | 116 ± 15a | 25.33 ± 3.75ab | 107 ± 15a | 15.48 ± 1.24a | 66 ± 5a | |
| Pelota 600 MPa/CUT | 25.67 ± 4.28a | 32.74 ± 1.64ab | 128 ± 15b | 41.83 ± 5.00b | 163 ± 8b* | 21.10 ± 2.20a | 82 ± 9a | |
| IG1 2 | Sanguinos Control | 0.55 ± 0.03ab | 0.63 ± 0.09b | 115 ± 11b | 0.85 ± 0.13b | 156 ± 17b | 0.31 ± 0.03a | 56 ± 5a |
| Sanguinos 600 MPa/CUT | 0.67 ± 0.06a | 0.74 ± 0.26a | 111 ± 29a | 0.81 ± 0.24a | 122 ± 25a | 0.46 ± 0.04a* | 69 ± 6a* | |
| Pelota Control | 1.44 ± 0.01b | 1.55 ± 0.15b | 108 ± 10b | 1.45 ± 0.23b | 101 ± 15b | 0.77 ± 0.06a | 53 ± 4a | |
| Pelota 600 MPa/CUT | 2.79 ± 0.17b* | 2.74 ± 0.09b* | 98 ± 3b* | 2.72 ± 0.14b* | 97 ± 1b* | 1.73 ± 0.14a* | 62 ± 5a* | |
| IG2 3 | Sanguinos Control | 1.51 ± 0.13b | 1.47 ± 0.14b | 98 ± 1c | 0.87 ± 0.10a | 58 ± 2b | 0.63 ± 0.05a | 42 ± 3a |
| Sanguinos 600 MPa/CUT | 1.50 ± 0.06b | 1.61 ± 0.18b* | 107 ± 8b | 1.60 ± 0.13b* | 107 ± 5b* | 0.89 ± 0.07a | 59 ± 5a* | |
| Pelota Control | 0.35 ± 0.00a | 0.45 ± 0.05a | 130 ± 14a | 0.42 ± 0.09a | 121 ± 26a | 0.25 ± 0.02a | 73 ± 6a | |
| Pelota 600 MPa/CUT | 0.64 ± 0.05b* | 0.56 ± 0.01b | 89 ± 6b | 0.55 ± 0.01b | 87 ± 5b | 0.35 ± 0.03a | 55 ± 4a | |
| IG3 4 | Sanguinos Control | 0.32 ± 0.03b | 0.33 ± 0.04b | 103 ± 2c | 0.26 ± 0.03b | 83 ± 2b | 0.15 ± 0.01a | 48 ± 3a |
| Sanguinos 600 MPa/CUT | 0.32 ± 0.01b | 0.33 ± 0.03b | 105 ± 6b | 0.30 ± 0.02b | 96 ± 3b* | 0.20 ± 0.02a* | 63 ± 5a* | |
| Pelota Control | 0.15 ± 0.00ab | 0.18 ± 0.00b | 125 ± 5b | 0.18 ± 0.03b | 120 ± 26b | 0.08 ± 0.01a | 57 ± 4a | |
| Pelota 600 MPa/CUT | 0.23 ± 0.01c | 0.20 ± 0.01b | 85 ± 1b* | 0.19 ± 0.00b | 80 ± 1b | 0.14 ± 0.1a* | 59 ± 5a | |
| IG4 5 | Sanguinos Control | 0.81 ± 0.06b | 0.73 ± 0.04b | 89 ± 2b | 0.53 ± 0.06a | 65 ± 3a | 0.49 ± 0.04a | 60 ± 5a |
| Sanguinos 600 MPa/CUT | 0.71 ± 0.03a | 0.83 ± 0.05a | 116 ± 1a* | 0.85 ± 0.19a | 120 ± 21a | 0.56 ± 0.04a | 79 ± 6a* | |
| Pelota Control | 0.23 ± 0.00a | 0.24 ± 0.03a | 104 ± 14a | 0.23 ± 0.10a | 97 ± 41a | 0.14 ± 0.01a | 59 ± 4a | |
| Pelota 600 MPa/CUT | 0.44 ± 0.04c* | 0.38 ± 0.00bc* | 85 ± 6b | 0.32 ± 0.01b | 72 ± 5b | 0.18 ± 0.01a | 40 ± 3a* | |
| IG5 6 | Sanguinos Control | 3.09 ± 0.18c | 2.89 ± 0.07bc | 93 ± 3c | 2.56 ± 0.08b | 83 ± 2b | 0.92 ± 0.07a | 30 ± 2a |
| Sanguinos 600 MPa/CUT | 2.82 ± 0.11b | 2.57 ± 0.11b | 91 ± 2b | 2.49 ± 0.42b | 88 ± 11b | 1.30 ± 0.11a* | 46 ± 4a* | |
| Pelota Control | 2.26 ± 0.01b | 2.29 ± 0.21b | 101 ± 9b | 2.26 ± 0.19b | 100 ± 8b | 1.26 ± 0.10a | 56 ± 4a | |
| Pelota 600 MPa/CUT | 5.10 ± 0.49c* | 4.78 ± 0.07bc* | 94 ± 8b | 3.91 ± 0.09b* | 77 ± 5b | 2.21 ± 0.18a* | 43 ± 4a* | |
Results are expressed as mean ± standard deviation (n = 3). Superscript lowercase letters indicate statistically significant differences (p ≤ 0.05) between digestive phases. * Indicate statistically significant differences (p ≤ 0.05) between treatments for the same variety. 1 mg/100 g fresh weight, 2 isorhamnetin glucosyl-rhamnosyl-rhamnoside (IG1), 3 isorhamnetin glucosyl-rhamnosyl-pentoside (IG2), 4 isorhamnetin hexosyl-hexosyl-pentoside (IG3), 5 isorhamnetin glucosyl-pentoside (IG4), and 6 isorhamnetin glucosyl-rhamnoside (IG5).
Figure 1Separation scheme of prickly pear fruit sliced quarters to process with high hydrostatic pressure (HHP) at 100, 300, and 600 MPa and evaluate the effect of the come-up time (CUT) and holding time at each pressure.